Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting

PHILADELPHIA (October 21, 2021) — Imvax , Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 36 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021. The poster highlights recent preclinical data for the company’s most advanced product candidate, IGV-001. The data elucidate potential mechanisms for the observed immune-stimulating and tumor-suppressing activity of IGV-001 seen in the Phase 1 clinical study for glioblastoma. “We’re pleased to share new insights into the mechanism of action of IGV-001, which are supportive of the clinical efficacy data we’ve previously reported,” said John Furey, Chief Executive Officer. “These insights are valuable both as we prepare for a Phase 2b trial in glioblastoma and as we expand our platform to address other solid tumor types.” Details of the poster presentation are as follows: Title: Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses Number: P218 Timing: November 13, 2021, 7:00 a.m-8:30 p.m. EST Presenter: Mark Exley, Ph.D., Chief Scientific Officer About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com . Media contact: Lisa Raffensperger [email protected] (617) 903-8783

The release as fetched from its publisher. imvax.com ↗